Jeffrey Chodakewitz - 10 Jun 2026 Form 4 Insider Report for Praxis Precision Medicines, Inc. (PRAX)

Reporting relationship: Director
Issuer ticker: PRAX
Reported as of: 10 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 12 Jun 2026, 17:24:20 UTC
Prior SEC filing: 27 Jun 2025
Next SEC filing: 23 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Alex Nemiroff, as Attorney-in-Fact

Key filing fact

Jeffrey Chodakewitz filed Form 4 for Praxis Precision Medicines, Inc. (PRAX) on 12 Jun 2026.

Key facts

This page summarizes Jeffrey Chodakewitz's Form 4 filing for Praxis Precision Medicines, Inc. (PRAX).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 12 Jun 2026, 17:24.

Change

Previous filing in this sequence was filed on 27 Jun 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001610876 Primary reporting owner

Chodakewitz Jeffrey

Relationship: Director
Address: C/O PRAXIS PRECISION MEDICINES, INC., 99 HIGH STREET, 30TH FLOOR, BOSTON
Signature: /s/ Alex Nemiroff, as Attorney-in-Fact
Signature date: 12 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

PRAX transaction

Common Stock

Award

Transaction value
Shares: +1,371
Change %
Price: $0.000000^*
Shares after: 1,371
Date: 10 Jun 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

PRAX transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +648
Change %
Price: $0.000000^*
Shares after: 648
Date: 10 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 648
Exercise price: $240.66
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Dr. Chodakewitz was awarded 1,371 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The restricted stock units vest in a single annual installment on the earlier of (i) June 10, 2027 or (ii) the date of the Issuer's 2027 annual meeting of stockholders. The restricted stock units may be settled only by delivering shares of the Issuer's common stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance.

Footnote F2

The shares subject to this option shall vest in twelve (12) equal monthly installments occurring on the 10th day of each month, with the first such installment occurring on July 10, 2026 and the final such installment occurring on the earlier of (i) June 10, 2027 or (ii) the date of the Issuer's 2027 annual meeting of stockholders.